This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Pharmacokinetics (PK) and bioequivalence (BE) studies serve as the foundation of determining the fate of drug products. Pharmacokinetic Modeling: Non-Linear Mixed Effects Modeling.
Moreover, it is a well-established fact that the systemic / local absorption and distribution of a therapeutic intervention is directly proportional to its bioavailability. Technology evaluation framework provides a value addition matrix for bioavailability enhancement approaches currently employed by industry stakeholders.
Conventional resveratrol products often face challenges like poor absorption and significant gastrointestinal side effects. Jotrol overcomes these barriers using patented micellar technology, enhancing bioavailability and enabling therapeutically effective doses.
dsm-firmenich has announced the launch of CBtru â an advanced formulated cannabidiol (CBD) drug product intermediate designed for oral solid delivery formats.
The stable gel matrix holds multiple ingredients, offering targeted release and enhanced bioavailability while optimizing patient experience. To address growing demand, Gelteq is expanding production capacity with a Good Manufacturing Practice (GMP)-certified facility, aiming for scalable, reliable output by 2025.
EverGrain Ingredients, a barley protein and fiber solutions company, recently received certification from the Upcycled Food Association (UFA) for its entire portfolio of products. The brand saw a unique opportunity to extract the excess barley to meet the global demand for sustainable, plant-based products. Barley Milk.
Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . The finished product dosage form, clinical development and the final products’ marketing and sales across the globe will be handled by Insud. .
The takeover of Metrics will bolster the expertise of Catalent in the development of integrated oral solid formulation, production and packaging to aid customers in streamlining and expediting their programmes. It will also aid in expanding the capacity of Catalent to manage highly potent compounds.
CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC). C4T can also earn up to $357m in milestone payments and receive low to mid-double-digit percentage royalties on net sales of the product in greater China.
It is formulated using a self-micro-emulsifying drug delivery system that improves the drug’s bioavailability and solubility. Scilex president and CEO Jaisim Shah said: “We are very pleased to announce the addition of Elyxyb to our current portfolio of two FDA-approved commercial non-opioid pain products. “We
One of Camargo’s differentiating offerings is the portfolio analysis, a high-level, integrated evaluation of the scientific, medical, regulatory, and commercial viability of each product within a sponsor’s portfolio. Each product is unique, and so is the associated development strategy. Why Conduct a Portfolio Analysis?
It delivers sustained BTK protein inhibition by optimising bioavailability, half-life and selectivity. Brukinsa is a small molecule Bruton’s tyrosine kinase (BTK) inhibitor that will be used to treat chronic lymphocytic leukaemia (CLL) in adult patients.
In 2020, the US Food and Drug Administration (FDA) issued a Guidance for Industry recommending that sponsors include plans for developing age-appropriate formulations of drug products in instances where adult formulations may not be suitable for paediatric patients. One of the most significant benefits of PDFs is their ease of administration.
The pharmaceutical company has forged a partnership with the nanotechnology specialist to use nanoparticle tech and formulation to advance its products.
Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups. Meanwhile, net product sales of Epidiolex grew by 22 percent to $196.2
Windtree Therapeutics noted that these product candidates are intended to be both oral and IV therapies. Dual mechanism SERCA2a activators work by inhibiting the Na+/K+ pump [an enzyme found in the membrane of all animal cells] and activating SERCA2a.
The China National Medical Products Administration (NMPA) has granted approval for BeiGene’s four applications for Brukinsa (zanubrutinib). The small molecule Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa has been specially designed for delivering sustained BTK protein inhibition by optimising bioavailability, half-life, and selectivity.
BeiGene has received marketing authorisations for Brukinsa (zanubrutinib) in Great Britain from the Medicines and Healthcare products Regulatory Agency (MHRA) to treat chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL).
Current treatment options for DES are dominated by a mix of prescription and over-the-counter (OTC) products. GlobalData anticipates CyclASol to be positioned as the superior cyclosporine due to its favorable tolerability profile and better bioavailability, with the potential to capture market share from other cyclosporine-based therapies.
It also aims to contribute to the pharmaceutical sector by facilitating cross-industry partnerships and research-based product development. The facility complements the company’s current pharma innovation centres in France and Singapore, and intends to improve the patient experience with modern oral dosage forms.
Lenz, Principal Medical Device Regulation Expert — For several years, FDA has requested that sponsors of drug or biologic led combination products identify essential performance requirements (EPRs) related to the device constituent in their applications. By Adrienne R. does not use this term.
Understanding both the significant competitive advantages that FDC products can offer, and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. More FDC products flowing into pharma pipelines.
During this stage, a team of lab technicians must identify the best way to manufacture the active pharmaceutical ingredient (API) into a suitable dosage form for pilot production. This is an exact science as the generation of too-fine or not-fine-enough powder will have a huge impact on the end-product.
Therefore, techniques and technologies that promote drug solubility and bioavailability are in high demand. Their focus is on improving drug solubility and bioavailability with powerful amorphous dispersion technologies, such as KinetiSol for poorly soluble compounds.
A final binding guidance published April 2017, Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications required that electronic submissions be formatted according to eCTD submission standards and defined technical rejection criteria.
When it comes to pharmaceutical, nutritional or cosmeceutical dosing, some of the most crucial parameters are safety, product effectiveness and patient adherence. They also offer enhanced bioavailability, exact dosing and an extended shelf life.
Placing traditionally siloed drug substance and drug product development activities within a single organization that also has commercial manufacturing capabilities accelerates clinical development and builds in quality and robustness of supply. Integrated drug substance and drug product services. Polymorphic form issues.
The pharmaceutical product landscape is rapidly and fundamentally changing with profound impact on research and development strategy and technology needs. The number of biopharmaceutical products show a considerable growth accounting for nearly a quarter of the new molecular entities approved in 2017.
Quotient Sciences was asked to select the best candidate based on material science and oral bioavailability considerations. We select the appropriate salt or physical form to optimize a molecule for both manufacturability and downstream product performance.
The difference between biologics vs small molecules in pharma drug development In pharmaceutical drug development, biologics and small molecules represent two distinct categories of medicinal products, each with their own unique characteristics, development processes, and mechanisms of action.
In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads to failure in obtaining approval authorization. Nanoparticles Contract Manufacturing.
Novaliq, a biopharmaceutical company specializing in ocular therapeutics, recently announced that their product Vevye (cyclosporine ophthalmic solution) 0.1 Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology.
Microparticles can be present as a contamination of products such as pharmaceuticals and electronics, or as an air pollutant. Alternatively, they can come as a product component of formulations such as cleaning agents and polymers.
As required by components of the 21 st Century Cures Act and the FDA Reauthorization Act, the FDA has sought to promote Patient-Focused Drug Development considerations into regulatory decision making, including product application approvals. FDA Publishes Draft Guidance on Adverse Drug Experience Reporting for INDs and BA/BE Studies .
SOL-578 is a best-in-class checkpoint kinase 1 (Chk1) inhibitor featuring high kinase selectivity and oral bioavailability which targets the DNA Damage Response (DDR) network. We believe that PharmaEngine can accelerate the development of this product based on our successful experience with a liposomal irinotecan, Onivyde®.”
In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.
Rykindo is something of a pathfinder product for Luye Pharma, however, and will allow the Chinese company to build a commercial presence in the US antipsychotics market as it brings forward its own pipeline of longer-acting candidates for schizophrenia and bipolar disorder.
Current treatments include hormonal therapies that focus on blocking the function of the estrogen receptor, curbing its production or degrading the receptor itself. Mutations in the ESR1 , however, have contributed to the rise of endocrine resistance. Orserdu is available in the form of 345 mg tablets to be taken once a day with food.
One of the key objectives behind the aforementioned developments is to overcome issues related to high costs associated with the design and production of such pharmacological interventions. Over 40 oral drug delivery technologies have been designed so far. For further information on this domain, check out the report –. Web: [link].
Despite increasing awareness, mental health issues like depression and anxiety continue to impact productivity and overall well-being in professional settings. With positive outcomes in preclinical models, EB-003 has confirmed oral bioavailability, adding to its therapeutic potential.
Product Name: ProstaStream. If within the first 60 days of receipt you are not satisfied with Wake Up Lean , you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked. ClickBank is the retailer of products on this site.
” Grünenthal already sells a topical capsaicin product called Qutenza for post-shingles nerve pain and diabetic nerve pain affecting the feet, and recently started a phase 3 trial that aims to extend its indications to include post-surgical neuropathic pain.
They indicate that the potential benefits over current protein and RNA-based approaches are “potency, selectivity, oral bioavailability, tissue distribution and central nervous system penetration.”. It has state-of-the-art proprietary assays to identify ligands that bind specifically to the structural pockets in many RNA molecules.
Companies specializing in dermatology and skincare have developed a range of products aimed at protecting the skin from harmful UV rays. These include broad-spectrum sunscreens, protective clothing and innovative skincare products developed using antioxidants and other protective agents.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content